Predictors of Mortality in Tocilizumab-Treated Severe COVID-19

Purpose: Tocilizumab is associated with positive outcomes in severe COVID-19. We wanted to describe the characteristics of nonresponders to treatment. Methods: This was a retrospective multicenter study in two respiratory departments investigating adverse outcomes at 90 days from diagnosis in subjec...

Full description

Bibliographic Details
Published in:Vaccines
Main Authors: Konstantinos Pagkratis, Serafeim Chrysikos, Emmanouil Antonakis, Aggeliki Pandi, Chrysavgi Nikolaou Kosti, Eleftherios Markatis, Georgios Hillas, Antonia Digalaki, Sofia Koukidou, Eleftheria Chaini, Andreas Afthinos, Katerina Dimakou, Ilias C. Papanikolaou
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Subjects:
COVID-19
tocilizumab
mortality
outcomes
severity
Online Access:https://www.mdpi.com/2076-393X/10/6/978

Internet

https://www.mdpi.com/2076-393X/10/6/978

Similar Items